Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

465 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Complete Response (CR) in a Previously-progressing Chronic Lymphocytic Leukemia (CLL) Patient Treated With Methionine Restriction in Combination With First-line Chemotherapy.
Morinaga S, Han Q, Mizuta K, Kang BM, Yamamoto N, Hayashi K, Kimura H, Miwa S, Igarashi K, Higuchi T, Tsuchiya H, Demura S, Hoffman RM. Morinaga S, et al. Among authors: demura s. Cancer Diagn Progn. 2025 Jan 3;5(1):21-26. doi: 10.21873/cdp.10407. eCollection 2025 Jan-Feb. Cancer Diagn Progn. 2025. PMID: 39758229 Free PMC article.
The Role of Microsurgery and Fluorescent-reporter Genes in Establishing Mouse Models for Real-Time Imaging of Metastatic Cancer-Cell Trafficking and Colony Formation: A Revolutionary and Disruptive Technology for Metastasis Research.
Morinaga S, Yamamoto N, Yamauchi K, Hayashi K, Kimura H, Miwa S, Igarashi K, Higuchi T, Tsuchiya H, Demura S, Hoffman RM. Morinaga S, et al. Among authors: demura s. Cancer Diagn Progn. 2024 Sep 1;4(5):544-557. doi: 10.21873/cdp.10362. eCollection 2024 Sep-Oct. Cancer Diagn Progn. 2024. PMID: 39238629 Free PMC article. Review.
Elevated-c-MYC-expressing Fibrosarcoma Cells With Acquired Gemcitabine Resistance Remain Sensitive to Recombinant Methioninase: A Potential Clinical Strategy for a Recalcitrant Disease.
Morinaga S, Han Q, Mizuta K, Kang BM, Bouvet M, Yamamoto N, Hayashi K, Kimura H, Miwa S, Igarashi K, Higuchi T, Tsuchiya H, Demura S, Hoffman RM. Morinaga S, et al. Among authors: demura s. Cancer Diagn Progn. 2025 Jan 3;5(1):8-14. doi: 10.21873/cdp.10405. eCollection 2025 Jan-Feb. Cancer Diagn Progn. 2025. PMID: 39758233 Free PMC article.
Prostate Cancer Patient With Lymph-node Metastasis Treated Only With Methionine Restriction Has Stable Disease for Two Years Demonstrated With PET/CT and PSMA-PET Scanning and PSA Testing.
Morinaga S, Han Q, Mizuta K, Kang BM, Yamamoto N, Hayashi K, Kimura H, Miwa S, Igarashi K, Higuchi T, Tsuchiya H, Demura S, Hoffman RM. Morinaga S, et al. Among authors: demura s. Cancer Diagn Progn. 2025 Jan 3;5(1):27-31. doi: 10.21873/cdp.10408. eCollection 2025 Jan-Feb. Cancer Diagn Progn. 2025. PMID: 39758238 Free PMC article.
Novel predictors of immune checkpoint inhibitor response and prognosis in advanced non-small-cell lung cancer with bone metastasis.
Asano Y, Yamamoto N, Demura S, Hayashi K, Takeuchi A, Kato S, Miwa S, Igarashi K, Higuchi T, Taniguchi Y, Morinaga S, Sone T, Okuda M, Matsumoto I, Yano S, Tsuchiya H. Asano Y, et al. Among authors: demura s. Cancer Med. 2023 Jun;12(11):12425-12437. doi: 10.1002/cam4.5952. Epub 2023 Apr 19. Cancer Med. 2023. PMID: 37076988 Free PMC article.
DNA-Binding Agent Trabectedin Combined With Recombinant Methioninase Is Synergistic to Decrease Fibrosarcoma Cell Viability and Induce Nuclear Fragmentation But Not Synergistic on Normal Fibroblasts.
Morinaga S, Han Q, Kubota Y, Mizuta K, Kang BM, Sato M, Bouvet M, Yamamoto N, Hayashi K, Kimura H, Miwa S, Igarashi K, Higuchi T, Tsuchiya H, Demura S, Hoffman RM. Morinaga S, et al. Among authors: demura s. Anticancer Res. 2024 Jun;44(6):2359-2367. doi: 10.21873/anticanres.17043. Anticancer Res. 2024. PMID: 38821601
Recombinant Methioninase Is Selectively Synergistic With Doxorubicin Against Wild-type Fibrosarcoma Cells Compared to Normal Cells and Overcomes Highly-Doxorubicin-resistant Fibrosarcoma.
Morinaga S, Han Q, Mizuta K, Kang BM, Sato M, Bouvet M, Yamamoto N, Hayashi K, Kimura H, Miwa S, Igarashi K, Higuchi T, Tsuchiya H, Demura S, Hoffman RM. Morinaga S, et al. Among authors: demura s. Anticancer Res. 2024 Aug;44(8):3261-3268. doi: 10.21873/anticanres.17144. Anticancer Res. 2024. PMID: 39060039
Overcoming High Trabectedin Resistance of Soft-tissue Sarcoma With Recombinant Methioninase: A Potential Solution of a Recalcitrant Clinical Problem.
Morinaga S, Han Q, Mizuta K, Kang BM, Sato M, Bouvet M, Yamamoto N, Hayashi K, Kimura H, Miwa S, Igarashi K, Higuchi T, Tsuchiya H, Demura S, Hoffman RM. Morinaga S, et al. Among authors: demura s. Anticancer Res. 2024 Sep;44(9):3785-3791. doi: 10.21873/anticanres.17203. Anticancer Res. 2024. PMID: 39197928
Recombinant Methioninase Increases Eribulin Efficacy 16-fold in Highly Eribulin-resistant HT1080 Fibrosarcoma Cells, Demonstrating Potential to Overcome the Clinical Challenge of Drug-resistant Soft-tissue Sarcoma.
Morinaga S, Han Q, Mizuta K, Kang BM, Sato M, Bouvet M, Yamamoto N, Hayashi K, Kimura H, Miwa S, Igarashi K, Higuchi T, Tsuchiya H, Demura S, Hoffman RM. Morinaga S, et al. Among authors: demura s. Anticancer Res. 2024 Sep;44(9):3777-3783. doi: 10.21873/anticanres.17202. Anticancer Res. 2024. PMID: 39197933
Extensive DNA Damage and Loss of Cell Viability Occur Synergistically With the Combination of Recombinant Methioninase and Paclitaxel on Pancreatic Cancer Cells which Report DNA-Damage Response in Real Time.
Morinaga S, Han Q, Mizuta K, Kang BM, Sato M, Bouvet M, Yamamoto N, Hayashi K, Kimura H, Miwa S, Igarashi K, Higuchi T, Tsuchiya H, Demura S, Hoffman RM. Morinaga S, et al. Among authors: demura s. Cancer Genomics Proteomics. 2024 Nov-Dec;21(6):585-590. doi: 10.21873/cgp.20475. Cancer Genomics Proteomics. 2024. PMID: 39467627 Free PMC article.
465 results